Factors Associated with Sexual Dysfunction in Individuals with Multiple Sclerosis
Implications for Assessment and Treatment

Samantha Domingo, PsyD; Tyler Kinzy, MS; Nicolas Thompson, MS; Shauna Gales, PA-C; Lael Stone, MD; Amy Sullivan, PsyD, ABPP

CME/CNE Information

Activity Available Online:
To access the article, post-test, and evaluation online, go to http://www.cmcscholar.org.

Target Audience:
The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS).

Learning Objectives:
1) Describe factors commonly associated with sexual dysfunction in patients with MS to identify those who may be at high risk.
2) Identify at least one validated tool to assess for sexual dysfunction in patients with MS.

Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit
The CMSC designates this journal-based activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Credit
The CMSC designates this enduring material for 0.75 contact hours (none in the area of pharmacology).

Disclosures:
Francois Bethoux, MD, Editor in Chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has received royalties from Springer Publishing and consulting fees from Ipsen and has performed contracted research for Biogen, Acadas Pharmaceuticals, Acorda Therapeutics, and Atlas5D.

Amy Sullivan, PsyD, ABPP, has received a consulting fee from and served on a speakers’ bureau for Novartis. One peer reviewer for the IJMSC has received royalties from UpToDate Inc and served on speakers’ bureaus for Allergan Inc and Astellas Inc. The other peer reviewer has disclosed no relevant financial relationships.

The staff at the IJMSC, CMSC, and Delaware Media Group who are in a position to influence content have disclosed no relevant financial relationships.

Note: Disclosures listed for authors are those applicable at the time of their work on this project and within the previous 12 months.

Method of Participation:
Release Date: August 1, 2018
Valid for Credit Through: August 1, 2019
In order to receive CME/CNE credit, participants must:
1) Review the continuing education information, including learning objectives and author disclosures.
2) Study the educational content.
3) Complete the post-test and evaluation, which are available at http://www.cmcscholar.org.

Statements of Credit are awarded upon successful completion of the post-test with a passing score of >70% and the evaluation.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC or Delaware Media Group.

Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health-care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

DOI: 10.7224/1537-2073.2017-059
© 2018 Consortium of Multiple Sclerosis Centers.
Sexual dysfunction is a common symptom of multiple sclerosis (MS) that often goes unreported by both the patient and the clinician. Sexual dysfunction can affect a person’s mood, relationships, daily functioning, and quality of life. Gaining a better understanding of the prevalence and nature of sexual dysfunction in individuals with MS would not only help identify patients with this problem but also determine contributing factors, which can inform treatment alternatives available to the patient.

Methods: Patients with a diagnosis of MS (n = 162) completed the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 during their neurology appointments at the Mellen Center for Multiple Sclerosis at Cleveland Clinic. These data were merged with Knowledge Program data collected as part of standard practice and included measures of mood, disability, and quality of life.

Results: Sexual dysfunction was present in 64.2% of the clinic sample. Patients with sexual dysfunction had significantly worse average MS-related disability and depressive symptom scores.

Conclusions: Sexual dysfunction is highly prevalent in the MS clinic sample. Assessment and treatment of depression may serve as a starting point for intervention in patients with MS who experience sexual dysfunction. Identifying individuals who are at risk for sexual dysfunction concerns may help with clinician and patient burden in terms of routine assessment of this symptom. Int J MS Care. 2018;20:191-197.
present study were 1) to survey the prevalence of sexual dysfunction in patients with MS in a clinic sample and 2) to further examine factors associated with sexual dysfunction, including demographic variables (ie, age, sex, race, median income, and marital status), mood, QOL, and disability.

Methods

Participants

Participants were recruited from a clinic sample at the Mellen Center for Multiple Sclerosis at Cleveland Clinic (Cleveland, OH). Participants who fit the study criteria and verbally expressed interest in participation completed the MSISQ-19 during their established neurology appointment. The survey was introduced by an advanced practice clinician and was completed by the participant in a private consultation room. Individuals aged 18 to 65 years with a diagnosis of MS who could speak, read, and write in English were included in the study. Individuals who were physically unable to complete the form on their own, those living in an assisted living facility, patients with severe cognitive impairment, and non–English-speaking patients were excluded from participation. This study was approved by the institutional review board at the Cleveland Clinic Foundation.

Measures

As part of standard practice, participants also completed other measures, including the MS Performance Scales, the Patient Health Questionnaire-9 (PHQ-9), and the Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10), and these data were available through the Knowledge Program Data Registry at Cleveland Clinic. The Knowledge Program data are collected via systematic administration of questionnaires to patients at each appointment, which helps track patients’ physical and emotional functioning over time. The MS Performance Scales is an instrument that measures disability in bladder control, cognitive functioning, fatigue, hand function, mobility, sensory symptoms, spasticity, and vision in MS. The PHQ-9 has been shown to be a reliable measure of depression severity. In addition, a medical record review was conducted to identify clinical covariates, including demographic information, current or past use of disease-modifying therapy, disease duration, present disease course, behavioral medicine consultations, and use of antidepressant medications.

Statistical Analyses

Sexual dysfunction was defined as a score of 4 or 5 on any MSISQ-19 item. Descriptive statistics were calculated for the entire cohort and stratified by the presence of any sexual dysfunction. Health status measure data were collected on the day of MSISQ-19 completion. If the data were not available on the day of completion, the data from the nearest visit within 210 days were substituted. This period was chosen because many patients had 6-month follow-ups with health status measure collection. Association between other measures and MSISQ-19 was assessed using multivariate linear regression models. Each model included the demographic covariates of age at time of completion (years), sex, race (white vs. nonwhite), marital status (married vs. not married), and median income by zip code (US dollars) as well as clinical covariates, including current or past use of disease-modifying therapy, disease duration (years), and present disease course categorized as progressive (clinically isolated syndrome, primary progressive, secondary progressive) or relapsing-remitting. Each subscale model had additional specific predictors of interest: primary included Timed 25-Foot Walk test score and PROMIS-10 item 6 inquiring about daily activities; secondary used PROMIS-10 items 7 and 8 detailing pain and fatigue; and tertiary included PHQ-9 score, PROMIS-10 item 2 asking about QOL, use of antidepressant drugs, and behavioral consultation reported in the previous year. Higher scores on the PROMIS-10 fatigue item represent less fatigue, whereas a higher score on the pain item indicates greater pain. The MS Performance Scales was also considered but ultimately excluded owing to a large proportion of missing data (>40%). All the analyses were computed using R, version 3.3.1 (R Core Team, R Foundation for Statistical Computing, 2016). A P < .05 was considered significant.

Results

Overall, 162 patients completed the MSISQ-19. Demographic and clinical characteristics are given in Table 1. Sexual dysfunction was present in 104 of the patients (64.2%). The cohort had a mean ± SD age of 45.6 ± 9.5 years and was majority female (n = 126 [77.8%]), white race (n = 132 [81.5%]), and married (n = 111 [68.5%]). Patients with and without sexual dysfunction did not differ in median income, age, sex, race, or marital status. Use of disease-modifying therapy and present disease course also did not differ significantly.
The MS Performance Scales, PHQ-9, Timed 25-Foot Walk test, and PROMIS QOL, everyday activities, fatigue, and pain scores were significantly worse in those with sexual dysfunction. Use of antidepressant medications and history of behavioral consultations were significantly higher in those with sexual dysfunction (Table 2). Missing data for the demographic and clinical variables ranged from 0% to 3.1% except for disease duration (22.2%). One individual had a confirmed diagnosis of MS but no clinical course information. Predictors of interest (Table 2) had moderate rates of missingness, ranging from 9.3% to 13%. Overall, 75.3% of patients were not missing any covariates and 87.8% were missing only one.

Multiple imputation was used to create 30 imputed data sets for multivariate analysis. The imputation model included MSISQ-19 items, demographic and clinical variables, and predictors of interest. Calculations were performed using the mice: Multivariate Imputation by Chained Equations in R 2.25 package. Continuous variables were imputed using predictive mean matching, and binary variables were imputed using logistic regression. Data were assumed missing-at-random based on visual inspection and sensitivity analyses. Linear regression models were computed in each imputed data set separately, with results combined using Rubin’s rules. Results for the primary, secondary, and tertiary models are presented in Table 3. A moderate degree of collinearity was present between the PROMIS item asking about daily activity and the Timed 25-Foot Walk test score in the primary model; the PROMIS item was retained. The PROMIS items, rated from 1 to 5, except for pain (rated 0-10), were strong predictors of associated MSISQ-19 subscales after adjustment for demographic and clinical factors. On average, an increase of 1 on the PROMIS everyday physical activities item decreased the MSISQ-19 primary score by 1.225. An increase of 1 on the PROMIS fatigue item, indicating less fatigue, was associated with a decrease of 3.493 on the secondary MSISQ-19 score, and an increase in the rating of pain increased the MSISQ-19 score by 0.726. Finally, tertiary sexual dysfunction increased by 1.798 per unit decrease in QOL.
Factors Associated with Sexual Dysfunction in MS

Participants who endorsed sexual dysfunction had higher PHQ-9 scores and were more likely to have been referred for a behavioral medicine consultation in the past year and to have received a prescription for an antidepressant medication. Patients with sexual dysfunction had higher PHQ-9 scores, and there were no significant differences in terms of sexual dysfunction domain.

Other studies have also found a strong association between depression severity and higher rates of sexual dysfunction. Depressive symptoms in MS can stem from both physiologic and psychological factors, which requires close assessment to determine appropriate treatment options (ie, pharmacologic and behavioral approaches). Many antidepressants can include loss of libido and delayed orgasm as common adverse effects, so it is imperative to focus on individual factors when recommending treatment options.

The findings of this study suggest that focusing on assessment of depression, pain, and fatigue can help identify individuals who are at risk of experiencing sexual dysfunction symptoms.

This study has several limitations. First, some of the health status measures were performed at different times. An increase of 5 units in the PHQ-9 score, considered a clinically meaningful change, was associated with an increase of 1.92 in the MSISQ-19 tertiary subscale. Patients who had a behavioral medicine consultation in the previous year had a score 3.07 higher than those who did not, on average. Use of antidepressant medications was not significantly associated with change in tertiary sexual dysfunction scores.

An increase of 5 units in the PHQ-9 score, considered a clinically meaningful change, was associated with an increase of 1.92 in the MSISQ-19 tertiary subscale. Patients who had a behavioral medicine consultation in the previous year had a score 3.07 higher than those who did not, on average. Use of antidepressant medications was not significantly associated with change in tertiary sexual dysfunction scores.

### Discussion

This study sought to explore the prevalence of sexual dysfunction in an MS clinic population and to identify variables associated with sexual dysfunction in MS. The results of the study demonstrated that sexual dysfunction is highly prevalent in a clinic sample at the Mellen Center for MS, consistent with existing literature. It was thought that older individuals with a progressive disease course would have a higher prevalence of sexual dysfunction. Interestingly, there were no differences between those who endorsed sexual dysfunction and those who did not in terms of age, sex, race, median income, marital status, or disease course. These results support the notion that sexual dysfunction is more prevalent in people with MS than in the general population. Moreover, participants who endorsed sexual dysfunction also had a higher prevalence of pain, fatigue, and depression and were more likely to have been referred for a behavioral medicine consultation in the past year and to have received a prescription for an antidepressant medication. Patients with sexual dysfunction had higher PHQ-9 scores, and there were no significant differences in terms of sexual dysfunction domain.

Other studies have also found a strong association between depression severity and higher rates of sexual dysfunction. Depressive symptoms in MS can stem from both physiologic and psychological factors, which requires close assessment to determine appropriate treatment options (ie, pharmacologic and behavioral approaches). Many antidepressants can include loss of libido and delayed orgasm as common adverse effects, so it is imperative to focus on individual factors when recommending treatment options. The findings of this study suggest that focusing on assessment of depression, pain, and fatigue can help identify individuals who are at risk of experiencing sexual dysfunction symptoms.

This study has several limitations. First, some of the health status measures were performed at different times...

### Table 2. Health status measures stratified by sexual dysfunction in relevant MSISQ-19 subscales

<table>
<thead>
<tr>
<th>Subscale</th>
<th>No sexual dysfunction</th>
<th>Sexual dysfunction</th>
<th>All (N = 162)</th>
<th>P value&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary, No. (%)</strong></td>
<td>86 (53.1)</td>
<td>76 (46.9)</td>
<td>162 (100)</td>
<td></td>
</tr>
<tr>
<td>T25FW test score, median (IQR)</td>
<td>5.2 (4.73-6.42)</td>
<td>6.3 (5.10-8.40)</td>
<td>5.60 (4.80-7.50)</td>
<td>.015</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>8 (9.3)</td>
<td>7 (9.2)</td>
<td>15 (9.3)</td>
<td></td>
</tr>
<tr>
<td>PROMIS – Everyday activities score, mean ± SD</td>
<td>4.21 ± 1.00</td>
<td>3.55 ± 1.20</td>
<td>3.88 ± 1.15</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>15 (17.4)</td>
<td>5 (6.6)</td>
<td>20 (12.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary, No. (%)</strong></td>
<td>89 (55.0)</td>
<td>73 (45.1)</td>
<td>162 (100)</td>
<td></td>
</tr>
<tr>
<td>MS Performance Scales score, mean ± SD</td>
<td>7.00 ± 4.43</td>
<td>16.22 ± 8.28</td>
<td>10.69 ± 7.70</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>35 (39.3)</td>
<td>37 (50.7)</td>
<td>72 (44.4)</td>
<td></td>
</tr>
<tr>
<td>PROMIS – Fatigue score, mean ± SD</td>
<td>3.32 ± 0.79</td>
<td>2.63 ± 0.80</td>
<td>3.01 ± 0.86</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>12 (13.5)</td>
<td>8 (11.0)</td>
<td>20 (12.3)</td>
<td></td>
</tr>
<tr>
<td>PROMIS – Pain score, mean ± SD</td>
<td>2.62 ± 2.54</td>
<td>5.23 ± 2.92</td>
<td>3.81 ± 3.01</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>12 (13.5)</td>
<td>9 (12.3)</td>
<td>21 (13.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Tertiary, No. (%)</strong></td>
<td>114 (70.4)</td>
<td>48 (29.6)</td>
<td>162 (100)</td>
<td></td>
</tr>
<tr>
<td>PHQ-9 score, mean ± SD</td>
<td>4.79 ± 4.06</td>
<td>10.41 ± 6.78</td>
<td>6.52 ± 5.67</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>15 (13.2)</td>
<td>8 (8.3)</td>
<td>19 (11.7)</td>
<td></td>
</tr>
<tr>
<td>PROMIS – Quality of Life score, mean ± SD</td>
<td>3.54 ± 0.90</td>
<td>2.62 ± 0.78</td>
<td>3.25 ± 0.96</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Missing, No. (%)</td>
<td>17 (14.9)</td>
<td>3 (6.2)</td>
<td>20 (12.3)</td>
<td></td>
</tr>
<tr>
<td>Behavioral medicine consult, No. (%)</td>
<td>12 (10.5)</td>
<td>11 (22.9)</td>
<td>23 (14.2)</td>
<td>.069</td>
</tr>
<tr>
<td>Antidepressants, No. (%)</td>
<td>52 (45.6)</td>
<td>32 (66.7)</td>
<td>84 (51.9)</td>
<td>.023</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, interquartile range; MSISQ-19, Multiple Sclerosis Intimacy and Sexuality Questionnaire-19; PHQ-9, Patient Health Questionnaire-9; PROMIS, Patient-Reported Outcomes Measurement Information System; T25FW, Timed 25-Foot Walk.

<sup>a</sup>Sexual dysfunction as determined by a score of 4 or 5 on MSISQ-19 items in the relevant primary, secondary, or tertiary subscale.

<sup>b</sup>Significance determined by Welch t test, Mann-Whitney U test, or χ² test as appropriate.
than when the MSISQ-19 was completed. Second, given that the Knowledge Program data are collected in a clinic setting versus a research setting, it is possible that rigorous methods of data collection were not applied, which generated some complications regarding missing data.

Despite these limitations, the results of this study have important clinical implications, as understanding the individual factors affecting sexual dysfunction will facilitate the development of evidence-based treatments. Given that time and efficiency are valued aspects of managing patient care, the development of treatment algorithms and workflow can help facilitate treatment delivery. Assessment and treatment of depression may serve as a starting point of intervention in patients with MS who experience sexual dysfunction. Assessment and treatment of sexual dysfunction in adults with MS is an important component of comprehensive care. Ideally, this should be part of a clinician’s routine assessment; however, many providers feel that they do not have the time or lack the training and comfort regarding treatment of sexual dysfunction. Knowing the impact of sexual dysfunction on QOL and general wellness, it is important to identify and offer treatment to individuals who experience these issues. We recommend narrowing assessment of sexual dysfunction to individuals who can be identified as being at risk, and, thus, help address some of these barriers by facilitating assessment and treatment. Due to the complexities of sexual dysfunction in MS, it will be important to identify appropriate means of intervention from an interdisciplinary perspective.

Table 3. Results of multivariate linear regression models for primary, secondary, and tertiary subscales of MSISQ-19

<table>
<thead>
<tr>
<th>Predictor of interest</th>
<th>Primary</th>
<th>Secondary</th>
<th>Tertiary</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROMIS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Everyday activities</td>
<td>–1.248 (–2.078 to –0.418); .003</td>
<td>–3.493 (–4.916 to –2.07); &lt;.001</td>
<td>–1.798 (–2.663 to –0.934); &lt;.001</td>
</tr>
<tr>
<td>Fatigue</td>
<td></td>
<td>0.726 (0.325 to 1.127); &lt;.001</td>
<td></td>
</tr>
<tr>
<td>Quality of life</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHQ-9</td>
<td></td>
<td>0.384 (0.237 to 0.53); &lt;.001</td>
<td></td>
</tr>
<tr>
<td>Behavioral medicine consult</td>
<td></td>
<td>3.07 (1.12 to 5.02); .002</td>
<td></td>
</tr>
<tr>
<td>Antidepressant drug use</td>
<td></td>
<td>–0.454 (–1.898 to 0.989); .535</td>
<td></td>
</tr>
</tbody>
</table>

Note: Results are presented as estimated coefficient (95% CI); P value. All the models were adjusted for age, sex, race, marital status, disease duration, disease-modifying therapy use, and clinical disease course.

Abbreviations: MSISQ-19, Multiple Sclerosis Intimacy and Sexuality Questionnaire-19; PHQ-9, Patient Health Questionnaire-9; PROMIS, Patient-Reported Outcomes Measurement Information System.

PRACTICE POINTS

- Sexual dysfunction is a highly prevalent symptom in individuals with MS that commonly goes unreported by the patient. Conversely, many clinicians choose not to assess for sexual dysfunction for a variety of reasons (eg, visit time limits, perceived patient discomfort, and perceived lack of competency in the area).
- Identifying factors that are commonly associated with sexual dysfunction in MS can help reduce clinician burden by understanding appropriate assessment for it in individuals at risk.
- The assessment and treatment of depression can serve as a starting point for intervention in individuals with MS who experience sexual dysfunction.
- Further understanding of sexual dysfunction has the potential to assist in the design of efficacious treatment alternatives and, thus, improve quality of life in individuals with MS.
References


IJMSC Now in PubMed Central and PubMed

The International Journal of MS Care (IJMSC) now participates in PubMed Central (PMC), a free electronic archive of full-text biomedical and life sciences journal literature at the US National Institutes of Health’s National Library of Medicine (NLM). Newly published articles can be accessed in PMC soon after publication, along with older articles going back to 2011. Citations and abstracts of these articles are retrievable in PubMed, the NLM’s journal abstract database (which includes the MEDLINE subset), through various types of searches.

PMC, which launched in 2000, serves as a digital counterpart to the NLM’s print journal collection. It is a repository for journal literature deposited by participating publishers, as well as for author manuscripts that have been submitted in compliance with the NIH Public Access Policy and similar policies of other research funding agencies. Currently, more than 3 million articles from nearly 5000 journals are archived in PMC.

The availability of IJMSC content in PMC and PubMed will make it more discoverable to researchers, health professionals, and the public. Each IJMSC search result in PubMed contains a link to the full-text article. This increased visibility and accessibility should lead to wider citation of IJMSC articles, helping to advance research and clinical practice in multiple sclerosis. Copyright to IJMSC material deposited in PMC remains with the Consortium of Multiple Sclerosis Centers, which is clearly indicated to PMC users.

In addition to being available in PMC and PubMed, IJMSC is indexed in the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Rehabilitation & Sports Medicine Source (EBSCO Publishing), as well as Scopus.